Crocin

Summary

Crocin (CHEMBL446785) is a phase-3 clinical-stage oligosaccharide antioxidant; indicated across 1 condition including osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 977 Da · C44H64O24

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL446785
Name	Crocin
Type	Oligosaccharide
Max phase	3
FDA approved	no
PubChem CID	5281233
ChEBI	CHEBI:79068
Molecular formula	C44H64O24
Molecular weight	977
InChIKey	SEBIKDIMAPSUBY-RTJKDTQDSA-N

SMILES: C/C(=C\C=C\C=C(\C=C\C=C(\C(=O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)/C)/C)/C=C/C=C(/C(=O)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)\C

IUPAC name: bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate

ChEBI definition: A diester that is crocetin in which both of the carboxy groups have been converted to their gentiobiosyl esters. It is one of the water-soluble yellow-red pigments of saffron and is used as a spice for flavouring and colouring food. Note that in India, the term ‘Crocin’ is also used by GlaxoSmithKline as a brand-name for paracetamol.

Pharmacological roles (ChEBI): antioxidant.

Other ChEBI roles (chemical / environmental): food colouring, plant metabolite, histological dye.

Also known as: .alpha.-crocin, Crocetin di-gentiobiose ester, Crocin, Crocetin di(beta-gentiobiosyl)ester, Crocin 1, crocin-1, SID29216153, crocetin di(beta-gentiobiosyl)ester, SID144205390, CROCIN

Patent coverage: 181 distinct patent families (336 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	4
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03375814	PHASE3	UNKNOWN	Evaluation Effect of Crocina on The Cellular Immune Responses in Osteoarthritis Patients
NCT04936490	PHASE1	UNKNOWN	Crocin Supplementation in CSCR
NCT06187818	Not specified	ACTIVE_NOT_RECRUITING	Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram
NCT04163757	Not specified	COMPLETED	The Effects of Crocin Supplementation on Metabolic Parameters, Oxidative Stress, AMP- Activated Protein Kinase and Inflammation-promoting Genes Expression in Peripheral Blood Mononuclear Cells in Patients With Type 2 Diabetes
NCT05504148	Not specified	UNKNOWN	Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy
NCT05696665	Not specified	UNKNOWN	Role of Saffron and Chamomile in the Management of Parkinson’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).